Login to Your Account



Alcobra to wind down MDX in ADHD, mull prospects in FXS

By Marie Powers
News Editor

Tuesday, January 17, 2017

Alcobra Ltd. is yanking development of MDX in the lead indication of ADHD in adults after the phase III registration trial, MEASURE, failed to demonstrate a statistically significant difference from placebo in change from baseline of the investigator rating of Conners' Adult ADHD Rating Scales, the primary endpoint.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription